TNFSF10 and cancer: We (Evdokiou et al, 2002), and others (Gliniak and Le, 1999; Desjosez et al, 2000; Gibson et al, 2000; Nagane et al, 2000; Yamanaka et al, 2000; Lacour et al, 2001; Mizutani et al, 2001), have shown that Apo2L/TRAIL can be successfully combined with currently used chemotherapeutic treatments to sensitise already resistant cancer cells to Apo2L/TRAIL-induced apoptosis.